Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Neuroblastoma 13Prostatic Neoplasms 11Leukemia 11Breast Neoplasms 11Melanoma 8Lymphoma 8Lymphoma, Non-Hodgkin 7Leukemia, Lymphocytic, Chronic, B-Cell 7Neoplasm Metastasis 6Myelodysplastic Syndromes 6Multiple Myeloma 6Leukemia, Myeloid, Acute 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Glioblastoma 5Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Fallopian Tube Neoplasms 4Breast Neoplasms, Male 4Lymphoma, Follicular 3Kidney Neoplasms 3Hodgkin Disease 3Glioma 3Carcinoma, Renal Cell 3Osteosarcoma 2Neoplasms, Plasma Cell 2Neoplasms 2Myeloproliferative Disorders 2Lymphoma, Mantle-Cell 2

Interventions

Radiation Dose Hypofractionation 2Immune Checkpoint Inhibitors 2Granulocyte-Macrophage Colony-Stimulating Factor 2envafolimab 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Advanced Refractory Solid Tumors × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT07327411 2026-01-08

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

Second Affiliated Hospital of Soochow University

Phase 2 Not yet recruiting
40 enrolled
Other solid neoplasm

Advanced Refractory Solid Tumors

NCT04892498 2022-08-09

Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)

Second Affiliated Hospital of Soochow University

Phase 2 Unknown
66 enrolled
Other solid neoplasm

Advanced Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡